Ignite Creation Date:
2025-12-25 @ 4:01 AM
Ignite Modification Date:
2026-03-13 @ 3:43 PM
Study NCT ID:
NCT04799002
Status:
RECRUITING
Last Update Posted:
2021-03-16
First Post:
2021-03-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Topotecan and Melphalan for Retinoblastoma
Sponsor:
Sun Yat-sen University
Organization:
Study Overview
Official Title:
Choice of Topotecan or Melphalan in Retinoblastoma Patients
Status:
RECRUITING
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Detailed Description:
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: